Beyond cyp2c19 - a new chapter in clopidogrel pharmacogenomics

Journal of Pharmacy Practice and Research

Volumn 41, Issue 1, 2011, Pages 14-16

  Polasek, Thomas M ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; CARBOXYLESTERASE; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE;

ACUTE CORONARY SYNDROME; CORONARY STENT; DRUG ACTIVATION; DRUG EFFICACY; DRUG METABOLISM; EDITORIAL; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; RISK; RISK ASSESSMENT; STENT THROMBOSIS; THROMBOCYTE; THROMBOEMBOLISM;

EID: 79960472920     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2011.tb00054.x     Document Type: Editorial

References (6)

1. Winslow R. Plavix rival gains from studies. Wall St 30 August 2010.
2. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated metaanalysis. Thromb Haemost 2010; 103: 841-8.
3. Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009; 37: 2145-52.
4. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-9.
5. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 2010; 304: 1821-30.
6. Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-16.